Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Retained Earnings (2020 - 2025)

Ovid Therapeutics' Retained Earnings history spans 6 years, with the latest figure at -$202000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings fell 477.14% year-over-year to -$202000.0; the TTM value through Dec 2025 reached -$202000.0, down 477.14%, while the annual FY2025 figure was -$202000.0, 477.14% down from the prior year.
  • Retained Earnings reached -$202000.0 in Q4 2025 per OVID's latest filing, down from -$126000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $5630.0 in Q1 2023 to a low of -$314.5 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$120.1 million, with a median of -$126.1 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 102.37% in 2023, then tumbled 5395645.31% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$171.4 million in 2021, then soared by 99.98% to -$42187.0 in 2022, then skyrocketed by 102.37% to $1000.0 in 2023, then crashed by 3600.0% to -$35000.0 in 2024, then plummeted by 477.14% to -$202000.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Retained Earnings are -$202000.0 (Q4 2025), -$126000.0 (Q3 2025), and -$69000.0 (Q2 2025).